Scientists report that lice populations in at least 25 states have developed resistance to over-the-counter treatments still widely recommended by doctors and schools. The researchers are presenting their work today at the 250th National Meeting & Exposition of the American Chemical Society (ACS), the world’s largest scientific society. The meeting features more than 9,000 presentations on a wide range of science topics and is being held here through Thursday.
Lice populations in the states in pink have developed a high level of resistance to some of the most common treatments. Illustration courtesy of Kyong Yoon, PhD.
Scientists report that lice populations in at least 25 states have developed resistance to over-the-counter treatments still widely recommended by doctors and schools. The researchers are presenting their work today at the 250th National Meeting & Exposition of the American Chemical Society (ACS), the world’s largest scientific society. The meeting features more than 9,000 presentations on a wide range of science topics and is being held here through Thursday.
“We are the first group to collect lice samples from a large number of populations across the U.S.,” says Kyong Yoon, PhD. “What we found was that 104 out of the 109 lice populations we tested had high levels of gene mutations, which have been linked to resistance to pyrethroids.”
Pyrethroids are a family of insecticides used widely indoors and outdoors to control mosquitoes and other insects. It includes permethrin, the active ingredient in some of the most common lice treatments sold at drug stores.
Yoon, who is with Southern Illinois University, Edwardsville, explains that the momentum toward widespread pyrethroid-resistant lice has been building for years. The first report on this development came from Israel in the late 1990s. Yoon became one of the first to report the phenomenon in the U.S. in 2000 when he was a graduate student at the University of Massachusetts, Amherst.
“I was working on insecticide metabolism in a potato beetle when my mentor, John Clark, suggested I look into the resurgence of head lice,” he says. “I asked him in what country and was surprised when he said the U.S.”
Intrigued, Yoon followed up on the lead and contacted schools near the university to collect samples. He suspected that the lice had developed resistance to the most common insecticides people were using to combat the bugs. So he tested the pests for a trio of genetic mutations known collectively as kdr, which stands for “knock-down resistance.” Kdr mutations had initially been found in house flies in the late ’70s after farmers and others had shifted to pyrethroids from DDT and other harsh insecticides.
Yoon found that many of the lice did indeed have kdr mutations, which affect an insect’s nervous system and desensitize them to pyrethroids. Since then, he has expanded his survey.
In the most recent study, he cast the widest net yet, gathering lice from 30 states with the help of a broad network of public health workers. Population samples with all three genetic mutations associated with kdr came from 25 states, including California, Texas, Florida and Maine. Having all the mutations means these populations are the most resistant to pyrethroids. Samples from four states - New York, New Jersey, New Mexico and Oregon - had one, two or three mutations. The only state with a population of lice still largely susceptible to the insecticide was Michigan. Why lice haven’t developed resistance there is still under investigation, Yoon says.
The solution? Yoon says that lice can still be controlled by using different chemicals, some of which are available only by prescription.
But the situation also offers a cautionary tale. “If you use a chemical over and over, these little creatures will eventually develop resistance,” Yoon says. “So we have to think before we use a treatment. The good news is head lice don’t carry disease. They’re more a nuisance than anything else.”
Source: American Chemical Society (ACS)
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.